AstraZeneca (AZN) Shares Down 0.5%

AstraZeneca PLC (LON:AZN) shares dropped 0.5% during trading on Monday . The company traded as low as GBX 4,734.50 ($63.72) and last traded at GBX 4,745 ($63.86). Approximately 1,823,066 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 2,180,000 shares. The stock had previously closed at GBX 4,767 ($64.16).

Several analysts have recently issued reports on AZN shares. Barclays reaffirmed an “overweight” rating and set a GBX 5,500 ($74.02) price objective on shares of AstraZeneca in a report on Monday, August 7th. set a GBX 4,100 ($55.18) price objective on AstraZeneca and gave the stock a “sell” rating in a report on Tuesday, August 8th. Investec raised AstraZeneca from a “hold” rating to a “buy” rating and decreased their price objective for the stock from GBX 5,000 ($67.29) to GBX 4,900 ($65.95) in a report on Wednesday, August 9th. J P Morgan Chase & Co set a GBX 4,200 ($56.53) price objective on AstraZeneca and gave the stock a “neutral” rating in a report on Wednesday, August 9th. Finally, Goldman Sachs Group set a GBX 3,900 ($52.49) price objective on AstraZeneca and gave the stock a “sell” rating in a report on Friday, August 18th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. AstraZeneca has a consensus rating of “Hold” and an average price target of GBX 5,164.45 ($69.51).

TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with's FREE daily email newsletter.

Leave a Reply